A hostile response to the USPTO’s guidelines

Anyone who attended the 2014 BIO International Convention in San Diego in June was left in no doubt about which subject is dominating discussion among IP lawyers working in the life sciences: the patent eligibility of natural products in the US following the Myriad and Mayo cases.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025

LSPN: Counsel grapple with AI’s impact on training and critical thinking

LSPN: Trump's policy storm causing chaos and confusion

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

Novartis settles with licensee of blood cancer therapy day before trial

Foley adds five-partner team from Perkins Coie and K&L Gates

A hostile response to the USPTO’s guidelines

Editor's picks

Editor's picks

More features